Mass Spectrometric Profiling of N-linked Oligosaccharides and Uncommon Glycoform in Mouse Serum with Head and Neck Tumor
Overview
Affiliations
N-linked oligosaccharides obtained from total serum of mice with implanted head and neck tumors were analyzed and compared with those from control samples of healthy mice. Methods used include a combination of a derivatization procedure with phenylhydrazine (PHN) and analysis by matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS). Oligosaccharides were enzymatically released from total serum with PNGaseF and purified by high-performance liquid chromatography (HPLC) on a reversed-phase column. Mass spectra contained ion peaks of labeled oligosaccharides and MS/MS experiments provided useful data for the structural elucidation of these compounds. More than 40 N-glycans with compositions characteristic of high-mannose, hybrid, complex, neutral, and sialylated structures were identified in the serum of tumoral mice. Significant differences between samples were observed with respect to the abundances of high mannose and hybrid glycans. These oligosaccharides showed higher relative intensities in the spectra obtained from the cancer sera. Complex sialylated oligosaccharides had similar abundances in both types of sera, with the exception of fucosylated biantennary disialylated oligosaccharide, which was mostly detected with lower abundance in control samples. In the MALDI spectra, several minor species corresponded to uncommon carbohydrates. These structures have been investigated in detail by MS/MS. Among these novel glycoforms, a few sialylated oligosaccharides without a free reducing end were identified. Also, glycans with an extra 60 u were observed and likely feature the presence of a 2-acetamido-2-deoxyoctose residue attached on antennae of 3- or 6-linked mannose.
[Applications of chromatography in glycomics].
Zheng Y, Cao C, Guo Z, Yan J, Liang X Se Pu. 2024; 42(7):646-657.
PMID: 38966973 PMC: 11224943. DOI: 10.3724/SP.J.1123.2023.12003.
Alterations of the Human Skin - and -Glycome in Basal Cell Carcinoma and Squamous Cell Carcinoma.
Moginger U, Grunewald S, Hennig R, Kuo C, Schirmeister F, Voth H Front Oncol. 2018; 8:70.
PMID: 29619343 PMC: 5871710. DOI: 10.3389/fonc.2018.00070.
Use of Mass Spectrometry to Screen Glycan Early Markers in Hepatocellular Carcinoma.
de Oliveira R, Ricart C, Martins A Front Oncol. 2018; 7:328.
PMID: 29379771 PMC: 5775512. DOI: 10.3389/fonc.2017.00328.
Meng B, Wang J, Wang Q, Serianni A, Pan Q Tetrahedron. 2017; 73(27-28):3932-3938.
PMID: 29104323 PMC: 5667659. DOI: 10.1016/j.tet.2017.05.073.
Reversed-phase separation methods for glycan analysis.
Vreeker G, Wuhrer M Anal Bioanal Chem. 2016; 409(2):359-378.
PMID: 27888305 PMC: 5203856. DOI: 10.1007/s00216-016-0073-0.